Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

ectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ECOG 5203)

Findings from this single-arm Phase 2 study provide encouraging data for the potential use of Nexavar in combination with docetaxel and cisplatin to treat patients with metastatic/advanced gastric/GEJ adenocarcinoma. The most common treatment-emergent adverse events included neutropenia, fatigue, anorexia, hand-foot reaction, nausea, diarrhea and dehydration.

The lead investigator for this study is Weijing Sun, MD, assistant professor of medicine, University of Pennsylvania, director of the Upper GI and Pancreatic-Biliary-Hepatic Cancer Group and the associate director of the GI Cancer Program. (abstract #4535).

Ovarian

Phase 2 Trial of Sorafenib in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

Preliminary findings from this Phase 2 study suggest that Nexavar is active and tolerated in patients with recurrent epithelial ovarian cancer. The most common treatment-emergent adverse events were dermatologic and metabolic.

The lead investigator for this study is Daniela Matei, M.D., Ph.D., assistant professor, department of medicine, Walther Oncology Center, Indiana University, Bloomington, IN. (abstract #5537).

"We continue to be encouraged by Nexavar's potential activity as a single agent or in combination with other chemotherapeutic agents in these early stage clinical trials in tumor types with high unmet treatment needs," said Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "The more data we compile from various studies in multiple tumor types, the better informed we are to determine the appropriate direction for further development of Nexavar in additional clinical cancer settings."

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has be
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Bronstein, Gewirtz & Grossman, LLC is investigating ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... advised to contact Peretz Bronstein or his ... info@bgandg.com or 212-697-6484. The investigation focuses ... violated federal securities laws. On September 16, ...
(Date:9/17/2014)... Sept. 17, 2014   OTEMR, Inc. , ONETOUCH ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  ONETOUCH EMR 2.0 was certified on July 14, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
(Date:9/17/2014)... Sept. 17, 2014  Lightbeam Health Solutions announced ... Organization (Physician Direct ACO) to deploy the Lightbeam ... providing better care while reducing costs. ... Physician Direct Accountable Care Organization is the ACO ... The OPNS mission is to be the premier ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- Present-day ... groups of ancient humans, according to a new ... descended from indigenous hunter-gatherers and early European farmers. ... samples revealed they are also the descendants of ... genetic material from this third ancestral group, researchers ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... Diabetics and dieters who turn to artificial sweeteners to ... any favors, a new Israeli study suggests. Artificial ... containing no calories, researchers found in human and mouse ... to alter the bacteria residing in the intestines in ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an ... however, little is known about how children process information ... preschool years. In a new study, a University of ... as they age, and a limit exists as to ... findings could help parents enhance their children,s vocabularies and ...
(Date:9/17/2014)... In a country where 77% of ... regular basis, how can Americans find healthy and fulfilling ... Stress Challenge , a 5-day interactive journey to putting ... From September 29th – October 3rd, the Hyland’s ... to specific topics that promote natural solutions for managing ...
(Date:9/17/2014)... Doheny HealthDay Reporter WEDNESDAY, ... beverage companies have made good on their pledge to cut ... The companies, acting together through the Healthy Weight Commitment Foundation, ... 2007 and 2012 and 1.5 trillion by 2015. They,ve actually ... collectively met their pledge and exceeded their pledge," said lead ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Babies learn words differently as they age, researcher finds 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3
... in patients aged 80 and older, researchers say , ... questions the widespread use of implantable cardiac devices in ... in the hospital after receiving the devices. , Patients ... implantable defibrillators and pacemakers, even though most clinical trials ...
... no longer safe on the road , MONDAY, April ... input from family members are the most useful tools in ... or other dementia sets in, according to new guidelines from ... assessments are usually more accurate than the patient,s own opinion ...
... expert says , MONDAY, April 12 (HealthDay News) -- A ... in the blood raises the risk of heart disease for ... however, is not seen in men, according to the report, ... . , The study, by researchers at Italy,s National Cancer ...
... Important advances in the fight against cancer have come as ... were previously unknown to scientists. A new study led ... activate a viral infection that, paradoxically, can help anti-viral medications ... a team of UNC School of Medicine scientists and the ...
... In an ongoing effort to scientifically validate the age-old belief ... of patients, The University of Texas M. D. Anderson Cancer ... the efficacy of incorporating yoga into the treatment program of ... ever awarded by the National Cancer Institute for the study ...
... pain can go on too long and be ineffective, study ... that many patients with terminal cancer don,t benefit from getting ... symptoms like pain. , The researchers, who reported their findings ... Cancer , say doctors are failing to properly adjust treatments ...
Cached Medicine News:Health News:Study Questions Use of Heart Device Implants in the Very Old 2Health News:Docs Issue Guidelines for Drivers With Dementia 2Health News:Docs Issue Guidelines for Drivers With Dementia 3Health News:Simple Carbs Pose Heart Risk for Women 2Health News:Simple Carbs Pose Heart Risk for Women 3Health News:UNC study offers first clinical evidence of anti-cancer drug triggering viral infection 2Health News:M. D. Anderson receives 4.5 million grant, largest ever for study of yoga and cancer 2Health News:Many Terminal Cancer Patients May Be Overtreated 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This dissector offers dual-action jaws, which are long, tapered, and angled 30 to simplify even difficult laparoscopic dissection....
Smooth, rounded working end manipulates organs less traumatically. Used as a general manipulative instrument....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: